Skip to main content
Equibles
SRTA logo

SRTA · Strata Critical Medical, Inc. · Documents

Track SRTA — free

Use SRTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SRTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.56 +0.30 (+5.70%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$491.43M
Shares
88.47M
Volume · Nov 6 1.35M Avg daily vol (3M) 944.97K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $197.14M up 34.3% 10-K filed Mar 3, 2026 Quarterly report New FY2026 Q3 Revenue $74.08M up 50.3% 10-Q filed Nov 3, 2026 Latest results New Financial results 8-K filed Nov 3, 2026 Earnings call New Q3 2026 earnings call Held Nov 3, 2026
2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Strata Critical Medical reported three-month revenue of $74.1 million, up 50.3% from $49.3 million, and gross margin of 22.7% versus 21.6%; net loss from continuing operations was $7,615 thousand.

Revenue $74.08M ▲ 50.3% Net loss $7.62M Diluted EPS -$0.09
Read from the MD&A section
Nov 3
Current report 8-K
Financial results

Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3% year-over-year, Adjusted EBITDA of $9.6 million and Free Cash Flow of $8.6 million; it announced a $20 million share repurchase authorization.

Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $72.51M ▲ 60.7% Net loss $10.52M Diluted EPS -$0.12
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $67.38M ▲ 87.4% Net income $2.15M Diluted EPS $0.03
Apr 14
Proxy statement DEF 14A Meeting May 28, 2026
Proxy statement AI summary on its way
Mar 3
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $197.14M ▲ 34.3% Net income $41.35M Diluted EPS $0.50
2025
Mar 13
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $248.69M ▲ 10.4% Net loss $27.31M Diluted EPS -$0.35
2024
Showing 1–50 of 113 documents
Key facts CIK 1779128 CUSIP 092667104 13F (30d) 70 filings 55 filers Visit website Investor relations